Impact of ezetimibe on markers of inflammation in patients treated with statins: a systematic review

[1]  Mark D. Huffman,et al.  Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data , 2022, The Lancet. Global health.

[2]  Carlos T. Nieto,et al.  Synthesis and Modeling of Ezetimibe Analogues , 2021, Molecules.

[3]  Cheol-Whan Lee,et al.  Statin/ezetimibe combination therapy vs statin monotherapy for carotid atherosclerotic plaque inflammation , 2021, Medicine.

[4]  ESC / EAS Guidelines for the Treatment of Dyslipidemias: Lipid Modification to Reduce Cardiovascular Risk , 2020, Digital Doctor.

[5]  J. H. Rudd,et al.  Low dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndrome (LILACS) , 2020 .

[6]  R. Diaz,et al.  Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT) , 2020, European heart journal. Quality of care & clinical outcomes.

[7]  F. Prati,et al.  Coronary inflammation: why searching, how to identify and treat it , 2020, European heart journal supplements : journal of the European Society of Cardiology.

[8]  G. Hindricks,et al.  2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. , 2019, Atherosclerosis.

[9]  J. H. Rudd,et al.  Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trial , 2018, BMJ Open.

[10]  F. Hu,et al.  Cardiovascular Disease Prevention by Diet Modification: JACC Health Promotion Series. , 2018, Journal of the American College of Cardiology.

[11]  N. Tian,et al.  Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction , 2017, Experimental and therapeutic medicine.

[12]  A. Sahebkar,et al.  Effect of ezetimibe on plasma adipokines: a systematic review and meta‐analysis , 2017, British journal of clinical pharmacology.

[13]  Fei Wang,et al.  Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. , 2017, International angiology : a journal of the International Union of Angiology.

[14]  C. Ballantyne,et al.  Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. , 2017, Atherosclerosis.

[15]  Lale Tokgözoğlu,et al.  Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel , 2017, European heart journal.

[16]  A. Sahebkar,et al.  Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms. , 2016, British journal of clinical pharmacology.

[17]  Jin-Ying Zhang,et al.  Effects of Combination of Ezetimibe and Rosuvastatin on Coronary Artery Plaque in Patients with Coronary Heart Disease. , 2016, Heart, lung & circulation.

[18]  R. Giugliano,et al.  Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT , 2015, Circulation.

[19]  J. Tobert,et al.  Statin intolerance: reconciling clinical trials and clinical experience. , 2015, JAMA.

[20]  G Van Camp,et al.  Cardiovascular Disease Prevention , 2012 .

[21]  Cesare R Sirtori,et al.  The pharmacology of statins. , 2014, Pharmacological research.

[22]  F. Fonseca,et al.  Effects of Ezetimibe on Endothelial Progenitor Cells and Microparticles in High-Risk Patients , 2014, Cell Biochemistry and Biophysics.

[23]  B. Okopień,et al.  The effect of simvastatin-ezetimibe combination therapy on adipose tissue hormones and systemic inflammation in patients with isolated hypercholesterolemia. , 2014, Cardiovascular therapeutics.

[24]  P. Hjemdahl,et al.  Lipid‐lowering treatment and inflammatory mediators in diabetes and chronic kidney disease , 2014, European journal of clinical investigation.

[25]  M. Kimura,et al.  Impact on optical coherence tomographic coronary findings of fluvastatin alone versus fluvastatin + ezetimibe. , 2014, The American journal of cardiology.

[26]  Francisco A H Fonseca,et al.  Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein. , 2013, Life sciences.

[27]  Y. Gupta,et al.  Hypolipidaemic and anti-inflammatory effects of fixed dose combination of atorvastatin plus ezetimibe in Indian patients with dyslipidaemia. , 2013, Singapore medical journal.

[28]  C. Mantzoros,et al.  Effects of simvastatin and ezetimibe on interleukin-6 and high-sensitivity C-reactive protein , 2013, Scandinavian cardiovascular journal. Supplement.

[29]  W. Weintraub,et al.  Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. , 2012, Atherosclerosis.

[30]  W. Tracz,et al.  Ezetimibe Combined With Simvastatin Compared With Simvastatin Alone Results in a Greater Suppression of Oxidative Stress and Enhanced Fibrinolysis in Patients After Acute Coronary Events , 2011, Journal of cardiovascular pharmacology.

[31]  E. Valentin,et al.  Comparison of the effects of combination atorvastatin (40 mg) + ezetimibe (10 mg) versus atorvastatin (40 mg) alone on secretory phospholipase A2 activity in patients with stable coronary artery disease or coronary artery disease equivalent. , 2011, The American journal of cardiology.

[32]  Sang-Wook Kim,et al.  Effects of Ezetimibe Added to Ongoing Statin Therapy on C-Reactive Protein Levels in Hypercholesterolemic Patients , 2011, Korean circulation journal.

[33]  B. Okopień,et al.  The Effect of Ezetimibe and Simvastatin on Monocyte Cytokine Release in Patients With Isolated Hypercholesterolemia , 2011, Journal of cardiovascular pharmacology.

[34]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[35]  S. Feasson,et al.  MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial. , 2008 .

[36]  C. Ballantyne,et al.  Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. , 2007, The American journal of cardiology.

[37]  E. Duffield,et al.  Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). , 2007, The American journal of cardiology.

[38]  D. Tribble,et al.  Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials. , 2006, Clinical therapeutics.

[39]  P. Sager,et al.  Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. , 2005, Atherosclerosis.

[40]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[41]  D. Tribble,et al.  A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. , 2004, Clinical therapeutics.

[42]  P. Sager,et al.  Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. , 2003, The American journal of cardiology.

[43]  P. Sager,et al.  Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia: A Prospective, Randomized, Double-Blind Trial , 2003, Circulation.

[44]  M. Kurusz,et al.  Efficacy and safety , 2021, Perfusion.

[45]  E. Choke,et al.  A randomised placebo-controlled double-blind trial to evaluate lipid-lowering pharmacotherapy on proteolysis and inflammation in abdominal aortic aneurysms. , 2011, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[46]  C. Suárez,et al.  Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study. , 2008, Clinical therapeutics.

[47]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[48]  Ames,et al.  PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .